Cecilie Ammitzbøll

Abstract Background and Objectives The anti-CD20 antibody ofatumumab is an efficacious therapy for multiple sclerosis (MS) through depletion of B cells. The purpose of this study was to examine the derivative effects of B cell depletion on the peripheral immune system and a direct treatment effect on T cells expressing CD20.

Highlights • Natalizumab decreases serum IgG in patients with progressive multiple sclerosis • Natalizumab decreases the frequency of plasmablasts among B cells in blood • Natalizumab increases the absolute counts in blood of B cell subset except for plasmablasts • Memory B cell absolute count in blood is lower in unstable natalizumab-treated patients • CD49d expression is markedly higher on plasmablasts compared to other B cell subsets • Cerebrospinal fluid plasmablasts frequency is reduced...

close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract With the discovery that the highly effective anti-CD20 antibody therapies developed to deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological properties of CD20+ T cells has emerged.